Marcello Casaccia Bertoluci1,2, Rodrigo Oliveira Moreira3,4,5, André Faludi6, Maria Cristina Izar7, Beatriz D Schaan8, Cynthia Melissa Valerio3, Marcelo Chiara Bertolami6, Ana Paula Chacra9, Marcus Vinicius Bolivar Malachias10, Sérgio Vencio11, José Francisco Kerr Saraiva12, Roberto Betti9, Luiz Turatti9, Francisco Antonio Helfenstein Fonseca7, Henrique Tria Bianco7, Marta Sulzbach6, Adriana Bertolami6, João Eduardo Nunes Salles13, Alexandre Hohl14, Fábio Trujilho15, Eduardo Gomes Lima9, Marcio Hiroshi Miname9, Maria Teresa Zanella16, Rodrigo Lamounier17, João Roberto Sá18, Celso Amodeo6, Antonio Carlos Pires19, Raul D Santos9. 1. Departamento de Medicina Interna, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2400, Porto Alegre, RS 90035-003 Brazil. 2. Serviço de Medicina Interna, Hospital de Clínicas de Porto Alegre (HCPA), UFRGS, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-903 Brazil. 3. Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Rua Moncorvo Filho, 90, Rio de Janeiro, RJ 20211-340 Brazil. 4. Faculdade de Medicina de Valença (FMV), Rua Sebastião Dantas Moreira, 40, Valença, RJ 27600-000 Brazil. 5. Faculdade de Medicina da Universidade Presidente Antônio Carlos (FAME/UNIPAC), Av. Juiz de Fora, 1100, Juiz De Fora, MG 36048-000 Brazil. 6. Instituto Dante Pazzanese de Cardiologia, Av. Dante Pazzanese, 500, São Paulo, SP 04012-180 Brazil. 7. Universidade Federal de São Paulo (UNIFESP), Rua Loefgren, 1350, São Paulo, SP 04040-001 Brazil. 8. UFRGS, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-903 Brazil. 9. Universidade de São Paulo (USP), Av. Dr. Enéas de Carvalho Aguiar, 44, São Paulo, SP 05403-000 Brazil. 10. Faculdade de Ciências Médicas de Minas Gerais, Alameda Ezequiel Dias, 275, Belo Horizonte, MG 30130-110 Brazil. 11. Universidade Federal de Goiás (UFG), 1ª Avenida, s/n, Setor Leste Universitário, Goiânia, GO 74605-020 Brazil. 12. Pontifícia Universidade Católica de Campinas (PUC-Campinas), Av. John Boyd Dunlop, s/n, Campinas, SP 13059-900 Brazil. 13. Faculdade de Ciências, Médicas da Santa Casa de São Paulo, Rua Dr. Cesário Motta Jr, 112, São Paulo, SP 01221-020 Brazil. 14. Universidade Federal de Santa Catarina (UFSC), Rua Profa. Maria Flora Pausewang, s/n, Florianópolis, SC 88040-970 Brazil. 15. Clínica de Endocrinologia e Metabologia, Av. Tancredo Neves, 1632/708, Salvador, BA 41820-020 Brazil. 16. UNIFESP, Rua Leandro Dupret, 365, São Paulo, SP 04025-011 Brazil. 17. Centro de Diabetes de Belo Horizonte, Rua Niquel, 31, Belo Horizonte, MG 30220-280 Brazil. 18. UNIFESP, Rua Botucatu, 740, São Paulo, SP 04023-002 Brazil. 19. Faculdade de Medicina de São José do Rio Preto, Av. Brg. Faria Lima, 5416, São José do Rio Preto, SP 15090-000 Brazil.
Abstract
BACKGROUND: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. MAIN BODY: The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. CONCLUSIONS: Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.
BACKGROUND: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. MAIN BODY: The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. CONCLUSIONS: Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Andrew I Geller; Nadine Shehab; Maribeth C Lovegrove; Scott R Kegler; Kelly N Weidenbach; Gina J Ryan; Daniel S Budnitz Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2015-03-14 Impact factor: 91.245
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Michael J Zellweger; Michael Maraun; Hans H Osterhues; Ulrich Keller; Jan Müller-Brand; Raban Jeger; Otmar Pfister; Thilo Burkard; Friedrich Eckstein; Stefanie von Felten; Stefan Osswald; Matthias Pfisterer Journal: JACC Cardiovasc Imaging Date: 2014-09-17
Authors: John Jeffrey Carr; David R Jacobs; James G Terry; Christina M Shay; Stephen Sidney; Kiang Liu; Pamela J Schreiner; Cora E Lewis; James M Shikany; Jared P Reis; David C Goff Journal: JAMA Cardiol Date: 2017-04-01 Impact factor: 14.676
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Roberta Maria Duailibe Ferreira Reis; Rossana Santiago de Sousa Azulay; Maria da Glória Tavares; Gilvan Cortês Nascimento; Sabrina da Silva Pereira Damianse; Viviane Chaves de Carvalho Rocha; Ana Gregória Almeida; Débora Cristina Ferreira Lago; Vandilson Rodrigues; Marcelo Magalhães; Carla Souza Sobral; Conceição Parente; Joana França; Jacqueline Ribeiro; Paulo Cézar Dias Ferraz; Carlos Alberto Azulay Junior; Dayse Aparecida Silva; Marília Brito Gomes; Manuel Dos Santos Faria Journal: Genes (Basel) Date: 2022-02-21 Impact factor: 4.096
Authors: Marcello Casaccia Bertoluci; João Eduardo Nunes Salles; José Silva-Nunes; Hermelinda Cordeiro Pedrosa; Rodrigo Oliveira Moreira; Rui Manuel Calado da Silva Duarte; Davide Mauricio da Costa Carvalho; Fábio Rogério Trujilho; João Filipe Cancela Dos Santos Raposo; Erika Bezerra Parente; Fernando Valente; Fábio Ferreira de Moura; Alexandre Hohl; Miguel Melo; Francisco Garcia Pestana Araujo; Rosa Maria Monteiro Castro de Araújo Principe; Rosane Kupfer; Adriana Costa E Forti; Cynthia Melissa Valerio; Hélder José Ferreira; João Manuel Sequeira Duarte; José Francisco Kerr Saraiva; Melanie Rodacki; Maria Helane Costa Gurgel Castelo; Mariana Pereira Monteiro; Patrícia Quadros Branco; Pedro Manuel Patricio de Matos; Pedro Carneiro de Melo Pereira de Magalhães; Roberto Tadeu Barcellos Betti; Rosângela Roginski Réa; Thaisa Dourado Guedes Trujilho; Lana Catani Ferreira Pinto; Cristiane Bauermann Leitão Journal: Diabetol Metab Syndr Date: 2020-05-24 Impact factor: 3.320
Authors: L M Pechmann; T H Jonasson; V S Canossa; H Trierweiler; G Kisielewicz; R R Petterle; C A Moreira; V Z C Borba Journal: Int J Endocrinol Date: 2020-10-29 Impact factor: 3.257